Lifecore Biomedical, Inc.
LFCR
$4.30
$0.061.30%
NASDAQ
| 09/30/2025 | 05/25/2025 | 02/23/2025 | 11/24/2024 | 08/25/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.31% | 0.47% | 7.23% | 16.47% | 23.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.31% | 0.47% | 7.23% | 16.47% | 23.42% |
| Cost of Revenue | 10.29% | 2.50% | -2.74% | 2.26% | 5.80% |
| Gross Profit | -4.06% | -3.71% | 34.71% | 57.30% | 79.95% |
| SG&A Expenses | -7.55% | 12.03% | 10.92% | 9.11% | 7.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.64% | 4.80% | 1.20% | 4.06% | 5.93% |
| Operating Income | 32.49% | -134.47% | 46.13% | 68.05% | 73.91% |
| Income Before Tax | -654.87% | -506.50% | -122.28% | 67.82% | 108.29% |
| Income Tax Expenses | 472.86% | -76.50% | -110.00% | -44.89% | -82.14% |
| Earnings from Continuing Operations | -668.69% | -514.93% | -116.98% | 67.66% | 108.14% |
| Earnings from Discontinued Operations | -- | -- | -99.24% | 103.32% | 102.83% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -596.83% | -422.29% | -121.19% | 80.30% | 106.58% |
| EBIT | 32.49% | -134.47% | 46.13% | 68.05% | 73.91% |
| EBITDA | 118.52% | -154.59% | 97.02% | 118.76% | 114.87% |
| EPS Basic | -582.76% | -431.05% | -118.57% | 79.18% | 106.73% |
| Normalized Basic EPS | -293.15% | -303.05% | -640.02% | 57.92% | 128.08% |
| EPS Diluted | -2,219.60% | -676.98% | -75.87% | 76.05% | 101.53% |
| Normalized Diluted EPS | -433.62% | -414.33% | -4,848.85% | 50.17% | 116.26% |
| Average Basic Shares Outstanding | 19.16% | 14.23% | 9.46% | 4.23% | 1.70% |
| Average Diluted Shares Outstanding | 8.45% | 3.93% | -0.45% | 4.16% | 11.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |